scholarly journals Current feasibilities of early ovarian cancer detection

2016 ◽  
Vol 65 (1) ◽  
pp. 69-74
Author(s):  
Anzhella S Khadzhimba
Keyword(s):  
Ovarian Cancer ◽  
Surgical Treatment ◽  
Sensitivity And Specificity ◽  
Cancer Detection ◽  
Preoperative Diagnosis ◽  
Ovarian Tumors ◽  
Ca 125 ◽  
Early Ovarian Cancer ◽  
Low Sensitivity ◽  
Malignancy Potential

We analyzed results of laparoscopic surgical treatment of 349 patients with ovarian tumors. Before surgery besides standard examination ultrasonography of pelvis and Ca-125 estimation was performed. After comparing of preoperative diagnosis with histopatological report was identified low sensitivity and specificity of ultrasonography and Ca-125 for assessment of tumor malignancy potential (32,35 %, 31,82 % and 72,55 %, 68,36 % respectively). It was concluded that nowadays the only method of early ovarian cancer detection is surgical treatment of patients with ovarian tumors, who have ultrasonography malignancy markers and increased Ca-125 level.

ANALYSIS OF UTERINE LAVAGE FOR EARLY OVARIAN CANCER DETECTION

2020 ◽  
Author(s):  
Diana Žilovič ◽  
Rūta Čiurlienė ◽  
Ieva Vaicekauskaitė ◽  
Rasa Sabaliauskaitė ◽  
Sonata Jarmalaitė
Keyword(s):  
Ovarian Cancer ◽  
Cancer Detection ◽  
Early Ovarian Cancer ◽  
Uterine Lavage

scholarly journals Determination of Serum CA125 and evaluate its efficiency as screening tool For Early Detection of Ovarian Tumors

2015 ◽  
Vol 12 (1) ◽  
pp. 55-62
Author(s):  
Baghdad Science Journal
Keyword(s):  
Ovarian Cancer ◽  
Early Detection ◽  
Screening Tool ◽  
Stage I ◽  
Ca 125 ◽  
Benign Tumors ◽  
Cancer Antigen 125 ◽  
Ovarian Cancers ◽  
Serum Ca125 ◽  
Low Sensitivity

Epithelial ovarian cancer is the leading cause of cancer deaths in women. To date, an effective screening tool for ovarian cancer has not been identified Several clinical and biological factors including serum cancer antigen 125 (CA- 125) have been assessed for prognostic and predictive relevance CA-125 is an epithelial marker derived from coelomic epithelium. It is elevated in 90% of advanced ovarian cancers and in 50% of early ovarian cancers while 20% of ovarian cancers have low or no expression of CA- 125 CA-125 concentrations were measured by Mini Vidas test (VIDAS CA125 II / BIOMERIEUX / France). The median CA-125 levels were significantly higher in the sera of ovarian cancer patients than in those with benign tumors and in healthy controls. However in correlation with stages the results showed that Patients with stage II have highly significant differences in level of serum CA125 compare with stage I in and stage III.CA125 showed low sensitivity to detect stage I carcinoma of the ovary which limits its value as an initial screening tool therefore combining of CA125 with other markers might enable improved early detection of ovarian cancer as compared with use of this marker alone.

Resection Guided by Antibodies (REGAJ) a Reappraisal after 10 Years

1998 ◽  
Vol 13 (4) ◽  
pp. 221-223 ◽  
Author(s):  
W. Jäger ◽  
S. Ackermann
Keyword(s):  
Ovarian Cancer ◽  
Monoclonal Antibody ◽  
Retrospective Analysis ◽  
Ovarian Tumors ◽  
Murine Monoclonal Antibody ◽  
Ca 125 ◽  
Clinical Value ◽  
Second Look

Between 1986 and 1990 50 patients with ovarian cancer were submitted to a procedure which we called REGAJ - resection guided by antibodies. Using the radiolabeled murine monoclonal antibody OC 125, microscopic ovarian tumors producing CA 125 were detected during second-look surgery by a hand-held probe. Retrospective analysis after 10 years revealed that this procedure resulted in the cure of 4 of 11 patients, who would otherwise have been considered tumor free during second-look surgery and not further treated. Previous problems associated with the method can now be solved so that the clinical value of the procedure should be reconsidered.

Early ovarian cancer detection by deep learning: Two-dimensional comprehensive serum glycopeptide spectra analysis

2020 ◽  
Vol 159 ◽  
pp. 79-80
Author(s):  
M. Mikami ◽  
K. Tanabe ◽  
K. Matsuo ◽  
M. Ikeda ◽  
M. Hayashi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Deep Learning ◽  
Cancer Detection ◽  
Two Dimensional ◽  
Spectra Analysis ◽  
Early Ovarian Cancer

scholarly journals Preoperative Measurement of Serum C-Reactive Protein: Is it Useful in the Differential Diagnosis of Adnexal Masses?

2017 ◽  
Vol 32 (1) ◽  
pp. 83-89 ◽  
Author(s):  
Adriana Yoshida ◽  
Sophie F. Derchain ◽  
Denise R. Pitta ◽  
Nathália Crozatti ◽  
Liliana A.L.A. Andrade ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Sensitivity And Specificity ◽  
Menopausal Status ◽  
Ovarian Tumors ◽  
Cancer Center ◽  
Benign Tumors ◽  
C Reactive Protein ◽  
Cross Sectional ◽  
Adnexal Masses ◽  
Reactive Protein

Background Serum biomarkers may help to discriminate malignant from benign adnexal masses with equivocal features on imaging. Adequate discrimination of such tumors is crucial for referring patients to either a specialized cancer center or a nonspecialized gynecology service. Aim We aimed to investigate whether the preoperative level of serum C-reactive protein (CRP), alone or combined with CA125 and menopausal status in the Ovarian Score (OVS), is useful in the prediction of malignancy in women with ovarian tumors. Methods This cross-sectional study included 293 patients who underwent surgery in a tertiary cancer center. Receiver operating characteristic (ROC) areas under the curves (AUC) for CRP, CA125 and OVS were calculated in different scenarios, as well as their sensitivity and specificity, using standard cutoff points (for CRP, 10 mg/L; for CA125, 35 U/mL). Results CA125 and the OVS performed significantly better than CRP alone in the differentiation of benign disease from epithelial ovarian cancer (EOC) (AUC = 0.86 for CA125, 0.79 for OVS, and 0.73 for CRP). OVS and CRP alone were superior to CA125 only in the differentiation of borderline ovarian tumors from advanced stages of EOC and non-EOC. Sensitivity and specificity were 52.5% and 83%, respectively, for CRP, 77.9% and 66.7% for CA125, and 71.3% and 67.8% for OVS. Conclusions OVS is as good as CA125 in the differentiation of benign tumors from ovarian cancer. The addition of CA125 and menopausal status to CRP enhanced the relatively low discriminatory power of isolated CRP.

Ultrasonographic markers and preoperative CA-125 to distinguish between borderline ovarian tumors and stage I ovarian cancer

2012 ◽  
Vol 92 (3) ◽  
pp. 285-292 ◽  
Author(s):  
Dimitrios Zacharakis ◽  
Nikolaos Thomakos ◽  
Ioannis Biliatis ◽  
Alexandros Rodolakis ◽  
Maria Simou ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Ovarian Tumors ◽  
Stage I ◽  
Ca 125 ◽  
Borderline Ovarian Tumors

Total Inhibin Is a Potential Serum Marker for Epithelial Ovarian Cancer

2007 ◽  
Vol 92 (7) ◽  
pp. 2526-2531 ◽  
Author(s):  
Anastasia Tsigkou ◽  
Daniele Marrelli ◽  
Fernando M. Reis ◽  
Stefano Luisi ◽  
Agnaldo L. Silva-Filho ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Postmenopausal Women ◽  
Serum Marker ◽  
Ovarian Tumors ◽  
Ca 125 ◽  
Surgical Removal ◽  
Specific Marker ◽  
Ovarian Cancers ◽  
Blood Specimens

Abstract Context: Total inhibin is the sum of precursors, subunits, and mature molecules of inhibin, which the normal ovary nearly stops to produce after menopause, whereas ovarian tumors still release. Objective: The aim of the present study was to evaluate whether the serum concentration of total inhibin has the sensitivity/specificity characteristics to become a diagnostic test for epithelial ovarian cancer in postmenopausal women. Design: This was a controlled, cross-sectional study. Setting: The study was conducted at the University of Siena. Patients: Blood specimens were collected from postmenopausal women with: 1) epithelial ovarian cancer, stage II-III (n = 89); 2) benign ovarian tumors (n = 25); 3) breast (n = 10), colon (n = 10), and stomach (n = 10) cancers; and 4) controls (n = 95). In the group of women with epithelial ovarian cancer, blood specimens were also collected after surgical removal of the tumor. In four cases of women with stage IIC mucinous tumor, blood specimens were collected during the follow-up time. Intervention: Total inhibin was measured by a new double-antibody ELISA. Results: Women with epithelial ovarian cancers showed serum total inhibin levels significantly higher than those with benign tumor or with nonovarian tumors or controls (P < 0.001). Patients with serous (n = 40) or mucinous tumors (n = 17) showed the highest total inhibin levels (P < 0.001). At 95% specificity, the total inhibin assay detected 37 of 40 (93%) serous tumors and 16 of 17 (94%) mucinous tumors. When total inhibin was combined with CA-125, all cases of serous and mucinous tumors were detected, and the overall sensitivity for epithelial ovarian cancers was 99% at 95% specificity. A significant decrease of total inhibin levels was shown in women with serous and mucinous carcinoma as result of surgery (P < 0.001). In the four women who were followed up, recurrence was associated to an increase of total inhibin levels. Conclusions: The present data show that total inhibin is a sensitive and specific marker of epithelial ovarian cancers in postmenopausal women. Total inhibin may therefore be combined with CA-125 for noninvasive diagnosis of epithelial ovarian cancer and may also be a useful serum marker to monitor disease-free intervals.

Sign in / Sign up

Export Citation Format

Share Document